Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

1. Sanmamed, N.
2. Gómez-Rivas, J.
3. Buchser, D.
4. Montijano, M.
5. Gómez-Aparicio, M.A.
6. Duque-Santana, V.
7. Torres, L.
8. Zilli, T.
9. Ost, P.
10. Maldonado, A.
11. López-Campos, F.
12. Couñago, F.